The high frequency of BRAF and NRAS mutations in particular provides important insights into the molecular heterogeneity of melanomas and potential sensitivity to targeted therapies, while NF1 and PTEN mutations further illustrate the diversity of driver alterations in this population (27). Here, PTEN is linked to melanoma.